Home » Topics » BioWorld Science

BioWorld Science
RSS

Mitsui Toatsu claims potential antitumor agents

Aug. 16, 1996

GEM-230 in preclinical testing at Hybridon

Aug. 16, 1996

ISIS-3521/CGP-64128A efficacy shown in preclinical models

Aug. 16, 1996

U.S. patent will issue covering GLIOMAB-H

Aug. 16, 1996

MAM-102: antineoplastic protein tyrosine kinase inhibitor

Aug. 16, 1996

Letrozole approved for marketing in France

Aug. 16, 1996

Sanofi Winthrop discloses topoisomerase II inhibitors

Aug. 16, 1996

Guilford to develop anticancer drugs in biodegradable polymers

Aug. 16, 1996

SuperGen acquires marketing rights for Barr generic drugs

Aug. 16, 1996

SS Pharm. discloses antitumor platinum complexes

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...